HI HR23

Urges the United States Food and Drug Administration, United States Surgeon General, and Hawaii's Congressional Delegation to consider requiring warning labels on products containing oxybenzone addressing human health risks.

Cites multiple studies linking oxybenzone exposure to health concerns including hormone mimicking effects, estrogen buildup, accumulation in fatty tissues, neonatal intestinal abnormalities, and transfer through breast milk.

Notes that the most recent FDA safety evaluation of oxybenzone was published in 1999, and current labeling requirements do not include warnings about potential health harms from oxybenzone exposure.

Emphasizes the need for warning labels on sunscreen and personal care products, particularly for women, pregnant or nursing mothers, and children, due to the absence of established safe exposure levels.

Directs transmission of certified copies of the resolution to the FDA Commissioner, United States Surgeon General, Hawaii's Congressional Delegation members, Director of Health, and Director of Commerce and Consumer Affairs.